FCRL5 and neoplasm: Furthermore, we demonstrated that FcRH5/BCMA TanCAR-T cells displayed superior anti-tumor capacity in the subcutaneous NCI-H929 xenograft model than mono-specific CAR-T cells, which could be translated into the significantly improved survival of the mice, coinciding with improved persistence and intratumoral infiltration of T cells in this group.